Anthracycline Topoisomerase Inhibitor drugs compared

Compare all 6 Anthracycline Topoisomerase Inhibitor drugs side by side, used for conditions such as breast neoplasms, leukemia, myelogenous, chronic, bcr-abl positive, leukemia, myeloid, acute. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores. The highest-rated is idarubicin hydrochloride.

Top-rated anthracycline topoisomerase inhibitor: 1. Idarubicin Hydrochloride · 2. Daunorubicin Hydrochloride · 3. Ellence

Anthracycline Topoisomerase Inhibitor drugs compared side by side, with pharmaranks' FDA recall-safety rating
Drug	Generic	Form	Status	Used for	Safety ratingFDA recall-based	Pharmacy pays
Idarubicin Hydrochloride	—	Injectable	Prescription	Breast Neoplasms, Leukemia, Myelogenous, Chronic, Bcr-Abl Positive	72/100	—
Daunorubicin Hydrochloride	—	Injectable	Prescription	Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma	68/100	—
Ellence	Epirubicin Hydrochloride	Injectable	Prescription	Breast Neoplasms	64/100	—
Idamycin Pfs	Idarubicin Hydrochloride	Solution	Prescription	Breast Neoplasms, Leukemia, Myelogenous, Chronic, Bcr-Abl Positive	64/100	—
Doxil (Liposomal)	Doxorubicin Hydrochloride	Injectable	Prescription	Urinary Bladder Neoplasms, Breast Neoplasms	Not yet rated	—
Doxorubicin Hydrochloride (Liposomal)	Doxorubicin Hydrochloride	Injectable	Prescription	Urinary Bladder Neoplasms, Breast Neoplasms	Not yet rated	—

The safety rating column is unique to pharmaranks — an independent 0–100 score from FDA regulatory recall data. Higher is safer. Not medical advice.

Best anthracycline topoisomerase inhibitor by condition

for breast neoplasms for bcr-abl positive chronic myelogenous leukemia for acute myeloid leukemia for precursor cell lymphoblastic leukemia-lymphoma for urinary bladder neoplasms for gastrointestinal neoplasms

Full ranking · 6 drugs

Frequently asked questions

What is the Anthracycline Topoisomerase Inhibitor drug class?

Anthracycline Topoisomerase Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 6 Anthracycline Topoisomerase Inhibitor products, each independently rated.

Are all Anthracycline Topoisomerase Inhibitor drugs the same?

No. Anthracycline Topoisomerase Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Anthracycline Topoisomerase Inhibitor drugs treat?

Per NIH RxClass drug-classification data, Anthracycline Topoisomerase Inhibitor drugs are used for conditions including breast neoplasms, leukemia, myelogenous, chronic, bcr-abl positive, leukemia, myeloid, acute, precursor cell lymphoblastic leukemia-lymphoma, urinary bladder neoplasms, gastrointestinal neoplasms.

Which Anthracycline Topoisomerase Inhibitor drug is best-rated?

By our independent rating, idarubicin hydrochloride currently ranks highest among Anthracycline Topoisomerase Inhibitor drugs. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.

Sources: the Anthracycline Topoisomerase Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class); how the class works is summarized from Anthracyclines - StatPearls - NCBI Bookshelf. Ratings are pharmaranks’ independent FDA recall-safety analysis.